GlaxoSmithKline seeks U.S. approval for triple lung drug

LONDON (Reuters) - GlaxoSmithKline said on Monday it had filed its new three-in-one inhaled lung drug for U.S. approval, putting it on track to reach the market ahead of rivals in 2017, assuming it wins a green light.